Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vocimagene amiretrorepvec-flucytosine gene therapy - Denovo Biopharma

Next Previous
Drug Profile

Vocimagene amiretrorepvec-flucytosine gene therapy - Denovo Biopharma

Alternative Names: DB-107; Flucytosine prodrug activating therapy - Forte Biosciences; Retroviral replicating viral; RRV; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosine

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tocagen
  • Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Immunotherapies; Pyrimidinones; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Gene transference; Prodrug activators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Anaplastic astrocytoma; Bladder cancer; Breast cancer; Glioblastoma; Glioma; Solid tumours

Most Recent Events

  • 20 Feb 2024 Denovo Biopharma plans a phase II trial for Glioblastoma and Anaplastic astrocytoma (Recurrent, Inoperable/unresectable) in USA (PO), in May 2024 (NCT06264388)
  • 25 Jul 2023 US FDA authorizes a phase II trial for DB 107 in Glioma
  • 25 Jul 2023 Denovo Biopharma plans a phase II trial in Glioma (First-line therapy)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top